Probatebeta
Target

TUBB4A

Tubulin beta-4A chain

As of the edition of 20 October 2026, TUBB4A (tubulin beta-4A chain, UniProt P04350) has 46 drugs tested at it and 45 companies on the list, 5 on route A and 3 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P04350
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
Inside the cell
Disease areas
Cancer; Skin and connective tissue; Urinary and reproductive; Lungs and airways; Digestive system; Blood and lymph; Immune system; Pregnancy and women's health
Registered trials of its drugs
7,727

Drugs at this target

StatusCount
Marketed17
Active5
Went quiet16
Stopped7
Status not established1
Total46
DrugStatusFurthest phaseUS protection
PaclitaxelMarketedPhase 4none listed
Docetaxel anhydrousMarketedPhase 4none listed
VincristineMarketedPhase 4none listed
VinorelbineMarketedPhase 4none listed
ColchicineMarketedPhase 4none listed
Brentuximab vedotinMarketedPhase 4Ends 2029
EribulinMarketedPhase 4Ended 2026
VinblastineMarketedPhase 4none listed
Trastuzumab emtansineMarketedPhase 4Ended 2025
CabazitaxelMarketedPhase 4Ended 2025
IxabepiloneMarketedPhase 3none listed
Polatuzumab vedotinMarketedPhase 3Ends 2031

12 of 46 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A5
Route B3
Engaged6
Undetermined31
Total on the list45
Three companies on route A or B, with the route only
CompanyRoute
EisaiRoute B
AbbVieRoute B
Celldex TherapeuticsRoute A

The other 42 companies at TUBB4A

In the product

45 companies in all; 42 are not named here, and no score is.

See the 45 companies at TUBB4A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at TUBB4A

Other targets in cancer

Companies holding approvals at TUBB4A